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Abstract 18 
Hypertension is the most significant modifiable risk factor for cardiovascular disease and 19 
contributes to the highest global burden of disease. Blood pressure (BP) measurement is 20 
among the most important of all medical tests, and it is critical for BP monitoring devices to 21 
be accurate. Comprehensive new evidence from meta-analyses clearly shows that many BP 22 
monitoring devices (including oscillometric machines and ‘gold standard’ mercury 23 
auscultation) do not accurately represent the BP within the arteries at the upper arm (brachial) 24 
or central aorta. Particular variability in the accuracy of BP devices compared with intra-25 
arterial BP has been demonstrated in the cuff BP range from prehypertension to grade I 26 
hypertension (systolic BP 120 – 159 to diastolic BP 80 – 99 mmHg). This is within the BP 27 
range that is most common among people worldwide and, thus almost certainly, feeding 28 
confusion around optimal hypertension guideline thresholds. At the individual level, 29 
inaccurate BP devices have major potential consequences for best practice patient 30 
management, where underestimation of true BP is a missed opportunity to lower 31 
cardiovascular risk (with therapeutics or lifestyle) and overestimation of true BP could lead to 32 
overmedication. Each problem leads to increased cost from preventable cardiovascular events 33 
and unnecessary medications. Altogether, there is a critical need to improve the accuracy 34 
standards of BP monitoring devices. In the meantime, out-of-office BP (24 hour ambulatory 35 
BP and/or home BP monitoring) or automated, unobserved in-office BP monitoring that take 36 
the average of multiple readings using validated devices are the best available options to 37 
determine BP control. 38 
 39 
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Hypertension is the single largest risk factor contributing to global burden of cardiovascular 41 
disease,1, 2 and is a problem affecting all countries irrespective of income status.3 About 1 in 3 42 
adults have hypertension, which is often asymptomatic, but once identified is eminently 43 
treatable with lifestyle (exercise and diet)4, 5 or blood pressure (BP)-lowering medication.6 44 
There is incontrovertible evidence that these interventions reduce risk for future disability and 45 
death from cardiovascular disease,7, 8 which underlies reasons why the accurate measurement 46 
of BP has been touted among the most important tests in all of clinical medicine.7 Yet 47 
somehow inexplicably there still remains controversial discordance between hypertension 48 
guideline recommendations.9  There are a multitude of potential sources of error that can 49 
contribute to inaccurate BP measurement from physiological anomalies (e.g. arrhythmias 50 
such as atrial fibrillation or large interarm BP differences) or technical issues such as subject 51 
preparation, cuff size and body position, to name but a few. Less well known is the source of 52 
error related to inaccuracy of the BP monitoring device itself, that is when a device does not 53 
accurately record the true level of BP within the large arteries. This problem, which could 54 
contribute to guideline discrepancies and threatens the opportunity to reduce disease burden 55 
from hypertension, is the focus of this review. 56 
Problems can arise when BP results are viewed from an individual rather than a group 57 
perspective. Figure 1 illustrates how a useful test from a population perspective may not 58 
deliver the results that are needed for individual decision-making. Cuff BP, despite its place 59 
as the clinical standard used daily around the world, may have these shortcomings. The 60 
mercury sphygmomanometer method was invented by Riva Rocci in 1896 and refined by 61 
Korotkoff in 1905.10 The fundamental measuring principles of cuff BP devices remain largely 62 
unchanged. While cuff BP is time-honored, it is also time to ask whether this antique method 63 
is the best tool to deliver optimal care to 21st century patients. Here, we bring to light several 64 
lines of evidence that raise serious accuracy concerns around BP monitoring devices even 65 
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when used under optimal conditions (e.g. correct cuff size, body position and in the absence 66 
of issues such as arrhythmias), and suggest that cuff BP may not be a good representation of 67 
the true intra-arterial BP values. This knowledge provides an opportunity to improve 68 
accuracy, but at the same time, warrants consideration of the potential impact of changing 69 
practice on patient diagnosis and management. 70 
What is cuff BP actually measuring? 71 
Of course, it is not the BP within the arm (brachial) artery that causes strokes and heart 72 
attacks, rather it is the BP within the central arteries directly interacting with the brain and 73 
heart. Thus, while cuff BP is measured at a peripheral (brachial) artery, the goal is to estimate 74 
the pressure load experienced by the central organs (supplied by the aorta) as the best marker 75 
of risk from high BP.11, 12 The Riva Rocci method was believed to represent central pressure 76 
as the cuff was applied at a large artery branch of the aorta, and therefore a minimal BP 77 
difference was expected.10 We now know that differences in systolic BP can occur such that 78 
among individuals with similar brachial systolic BP (e.g. 150 mmHg) the central aortic 79 
systolic BP could vary substantially under resting conditions – e.g. from 120 to 150 mmHg 80 
(but generally always lower).13 Thus, even if an accurate measure of cuff (brachial) systolic 81 
BP could be derived, the true risk related to BP at the central aortic level may be markedly 82 
overestimated in some people. This discrepancy between central and peripheral systolic BP is 83 
exacerbated during exercise even at light intensities14 similar to that experienced during 84 
normal daily life when ambulatory BP monitoring may be undertaken. 85 
Adding further complexity to accurate assessment of BP is the knowledge that BP-86 
lowering drugs can differentially affect central aortic BP compared with arm BP. Indeed, 87 
modern anti-hypertensives typically lower central systolic BP more than that at the arm,15 but 88 
even more critically, it is possible for drugs to elicit large central systolic BP drops in the 89 
absence of any appreciable change to arm systolic BP.16 These central to peripheral BP 90 
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discrepancies create the intriguing possibility that clinicians could be ‘chasing’ the wrong BP 91 
targets when clinical decisions are guided by cuff BP. These underlying factors could help 92 
explain discrepant results from large clinical trials of optimal cuff BP targeting among 93 
different patient populations. 94 
The above information provides the basic rationale for development of non-invasive 95 
devices aiming to provide a more accurate measure of central aortic BP, which should 96 
theoretically lead to better clinical outcomes. Many such devices are now commercially 97 
available,17 but there is minimal clinical trial data18, 19 and have not been widely adopted in 98 
clinical practice. Key criticisms relate to accuracy concerns for determining the true central 99 
BP (e.g. compared with an invasive reference standard) - ironically, because conventional 100 
cuff BP is still needed for calibration purposes and this induces unacceptable error.20 101 
Currently, there is a general sentiment in favor of keeping with time-honored cuff BP in 102 
preference to any other method, until a strong case for change is provided.21 103 
What is the evidence around accuracy concerns with cuff BP? 104 
It is widely appreciated that auscultation and oscillometric cuff BP methods have a tendency 105 
towards underestimating true brachial systolic BP on the one hand, but overestimating 106 
diastolic BP on the other.22 This could have the unintended beneficial outcome of cuff BP 107 
providing a good estimate of central aortic BP, since systolic BP is usually lower and 108 
diastolic BP usually higher at the aorta compared with the brachial artery. Yet, the first study 109 
to definitively address the issue on the accuracy of cuff BP was only recently published.23 In 110 
this work, cuff BP was compared with intra-arterial brachial BP or aortic BP recorded at the 111 
same (or similar) time under resting conditions, mostly among people having coronary 112 
angiographic procedures. These were individual participant data meta-analyses from the 113 
1950’s to the current day that provided the most comprehensive analysis of cuff BP accuracy 114 
to date. Comparisons of ambulatory BP with intra-arterial measurements24 were not 115 
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undertaken because of scarce availability of studies and protocols that were highly divergent 116 
from investigations in which monitoring was conducted at rest. Similarly, the meta analysis 117 
avoided studies among patients in hyperacute conditions such as stroke,25 critical illness or 118 
those undergoing surgery, or during maneuvers such as Valsalva or exercise, because of large 119 
hemodynamic shifts that may have influenced cuff BP accuracy, and thus potentially 120 
introduced bias into the analysis.  121 
In the meta-analyses, when people were categorized according to guideline 122 
hypertension thresholds, cuff BP had reasonable concordance with either brachial or aortic 123 
intra-arterial BP among people with normal cuff BP (<120/80 mmHg; 60% and 79% 124 
agreement, respectively) or grade II hypertension (≥160/100 mmHg; 80% and 76% 125 
agreement, respectively) – the extreme ends of the BP risk spectrum. But for those in the 126 
middle risk spectrum with cuff BP in the range from prehypertension to grade I hypertension 127 
(120 – 159 to 80 – 99 mmHg), concordance with either intra-arterial brachial BP or aortic BP 128 
was only 50% to 57%. Results were consistent for auscultation (‘gold standard’) and 129 
oscillometric methods. These are crucial observations because the BP zone with the least 130 
accuracy is that which comprises most people worldwide,26 and thus is a problem that would 131 
almost certainly be contributing to confusion around optimal hypertension thresholds and 132 
discrepancy between guidelines.21, 27 133 
On average, cuff BP underestimated intra-arterial brachial systolic BP by 5.7 mmHg 134 
and overestimated diastolic BP by 5.5 mmHg, leading to a sizeable 12 mmHg 135 
underestimation of pulse pressure. For intra-arterial aortic BP, the cuff BP variably 136 
underestimated and overestimated systolic BP between different cuff BP devices and 137 
techniques. Only 33% of cuff BP’s were within ±5 mmHg from intra-arterial values (see 138 
figure 2). Age and body mass index appeared to have a modulating influence on the 139 
magnitude of cuff BP inaccuracy but more work is needed to understand key influential 140 
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factors. Overall, these are sobering data, strongly supporting a need for improved cuff BP 141 
accuracy standards. 142 
What are the potential clinical ramifications of inaccurate cuff BP? 143 
As already alluded, the availability of inaccurate BP devices has a variety of potentially 144 
serious consequences for clinical practice. For example, the interpretation of results from 145 
seminal clinical trials that influence guidelines may be profoundly altered by having regard to 146 
the accuracy performance of the BP device/s used in the trial – could there have been 147 
systematic or random errors related to underlying BP level or patient characteristics? To our 148 
knowledge these questions have not been probed to date.  At the population level, a relatively 149 
small error in cuff BP measurement can have major consequences for best practice patient 150 
management. In the United States, data projections show that cuff BP inaccuracy of as little 151 
as 5 mmHg could misclassify BP control among 48 million people each year.28 The meta-152 
analyses data above indicate that error of this magnitude (and more) is likely to be the norm 153 
rather than an exception.23 For those individuals where BP is underestimated, there is a 154 
missed opportunity to lower cardiovascular risk with therapeutics or lifestyle advice. For 155 
individuals where BP is overestimated there is potential risk of overmedication and adverse 156 
side effects. Irrespective of the direction in cuff BP inaccuracy the public health outcome is 157 
the same – increased cost from preventable cardiovascular events and unnecessary 158 
medications. 159 
What are the solutions? 160 
Concerns about the accuracy of cuff BP should not detract from current efforts to measure 161 
and control BP. In addition to the challenges of approximating central pressure, a multitude 162 
of problems may contribute to hypertension misdiagnosis if doctor-measured BP is relied 163 
upon as the sole source of information about BP control (e.g. white coat hypertension and 164 
lack of time to measure BP according to guideline criteria). The best available options to 165 
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confirm diagnosis beyond doctor-measured BP are out-of-office measurement of 24 hour 166 
ambulatory BP29, 30 or home BP monitoring,31, 32 or automated in-clinic (unobserved) BP33 167 
using validated BP devices. In general, 24 hour ambulatory BP has the highest sensitivity for 168 
predicting cardiovascular clinical outcomes34 (see table 1 summary).  169 
Although, the same (relatively inaccurate) BP methods are used with out-of-office 170 
BP, these techniques acquire multiple BP measures over time, which may reduce error 171 
margin and seem to offer more clinical information about chronic BP exposure. There is 172 
strong evidence that these methods sizably out-perform office BP in terms of association with 173 
cardiovascular outcomes.35 In this regard, the new US guidelines that place greater emphasis 174 
on using out-of-office BP is a step forward for better patient management with potentially 175 
more accurate assessment of BP.27 However, the suggested lowering of the hypertension 176 
threshold to 130/80 mmHg does little to address BP-related cardiovascular risk if the devices 177 
in the hands of doctors are substantially inaccurate. Ultimately, we need more accurate ways 178 
to measure BP and this is an urgent research imperative, which must surely lead to greater 179 
agreement between international hypertension guidelines, improved diagnostic confidence, 180 
improved clinical decisions and better patient outcomes.   181 
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Figure 1. Illustration of how an unacceptable level of diagnostic misclassification at the 296 
individual level may provide reasonable diagnostic performance at the population level. 297 
In this example, the individual misclassification of 40% of the intermediate risk group could 298 
still provide positive predictive value of 78% and negative predictive value of 89% because 299 
of high performance in low and high risk groups. Green = correctly classified low risk; red = 300 
correctly classified high risk; black = incorrectly classified low risk; blue = incorrectly 301 
classified high risk. 302 
Figure 2. Individual brachial cuff and intra-arterial blood pressure (BP) differences. 303 
Plots of brachial cuff and intra-arterial brachial (A; n=735), as well as brachial cuff and intra-304 
arterial aortic (B; n=1823) systolic BP. The mean of the brachial cuff systolic BP and intra-305 
arterial systolic BP is on the x-axis, and the mean difference between brachial cuff systolic 306 
BP and the intra-arterial systolic BP is on the y-axis. The proportion of brachial cuff SBP 307 
values within ±5 mmHg of the intra-arterial systolic BP measures is represented by the green 308 
dashed line, and is reported under the ±5 bar. The same presentation is provided for cuff 309 
systolic BP values within ±10 mm Hg (orange dotted line) and ±15 mm Hg (red dot-dashed 310 
line). The solid blue horizontal line represents the mean systolic BP difference calculated as 311 
brachial cuff minus intra-arterial BP. Reprinted from Picone et al J Am Coll Cardiol (2017)23 312 
with permission from Elsevier.  313 
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Table 1. Summary of key take home messages 314 
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 323 
 324 
• Hypertension is an extremely important cardiovascular risk factor that needs 
to be detected using blood pressure (BP) monitoring devices that are 
accurate. 
• Substantial new evidence definitively shows that many BP monitoring 
devices are not accurate – this includes the ‘gold standard’ mercury 
auscultation. This problem is highly likely to contribute to discrepancy 
among international hypertension guidelines. 
• There is a critical need to improve the accuracy standards of BP monitoring 
devices. 
• In the meantime, out-of-office BP (24 hour ambulatory BP and/or home BP 
monitoring) or automated, unobserved in-office BP monitoring that take the 
average of multiple readings are the best available options to determine BP 
control. 
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